Ranibizumab ophthalmic Pregnancy and Breastfeeding Warnings
Ranibizumab ophthalmic is also known as: Lucentis
Ranibizumab ophthalmic Pregnancy Warnings
Ranibizumab has been assigned to pregnancy category C by the FDA. Animal studies have demonstrated skeletal abnormalities in fetuses with trough exposures up to 13 times higher than predicted Cmax levels with a single eye treatment in humans, but these abnormalities were not seen at doses which resulted in trough exposures equivalent to a single eye treatment in humans. It is not known whether ranibizumab administered to a pregnant woman can cause fetal harm or affect reproduction. There are no controlled data in human pregnancy. Since ranibizumab may pose a risk to embryo-fetal development and reproductive capacity, it should be given during pregnancy when need has been clearly established.
Ranibizumab ophthalmic Breastfeeding Warnings
There are no data on the excretion of ranibizumab into human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution is recommended if ranibizumab is administered to a nursing woman.
- Ranibizumab use while Breastfeeding (in more detail)
- ranibizumab Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.